JKJoshua L. Krieger

Joshua L. Krieger

*This is an algorithmically generated author record based on publicly available information.

Joshua L. Krieger has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • How Important Is Editorial Gatekeeping? Evidence from Top Biomedical Journals

    by Joshua L. Krieger, Kyle R. Myers, Ariel D. Stern

    We examine editors’ influence on the scientific content of academic journals by unpacking the role of three major forces: journals’ stated missions, the aggregate supply of and demand for specific topics, and scientific homophily via editorial gatekeeping. In a sample of top biomedical journals, we find the first two forces explain the vast majority of variation in published content. The upper bound of the homophily effect is statistically significant but practically much less important. Marginal changes to the composition of editorial boards do not meaningfully impact journals’ content in the short run. However, we cannot rule out persistent or pervasive frictions in the publication process.


  • Open Access

    Standing on the shoulders of science

    by Joshua L. Krieger, Monika Schnitzer, Martin Watzinger

    Research Summary: Today's innovations rely on scientific discoveries of the past, yet only some corporate R&D builds directly on scientific output. In this article, we analyze U.S. patents to investigate how firms generate value by building on prior art “closer” to science. We show that patent value is decreasing in distance‐to‐science. Overall, we find a science premium within firms ranging from 5.0 to 18.3%. If we allow for firm sorting into different modes of R&D based on their relative advantage, that is, when we do not control for firm fixed effects, we find an even larger science premium: patents building directly on scientific publications are 4.0–42.3% more valuable than patents in the same technology that are not directly based on science. Managerial Summary: Building on scientific research allows firms to capture significantly more value from their inventions. By analyzing U.S. patents and their linkages to scientific publications, our paper describes the relationship between invention “proximity” to the scientific literature and public firm valuations—as measured in abnormal stock market returns. Our findings indicate that patents building on science are 5.0–18.3% more valuable. If we account for variations in R&D strategies among firms, the premium becomes even larger, ranging from 4.0 to 42.3%. Further, the results show that the value‐enhancing benefits of integrating scientific insights into R&D are greater for firms with more experience building on science. Together, the results underscore the competitive advantages of using science as a foundation for corporate innovation.


  • Find and Replace: R&D Investment Following the Erosion of Existing Products

    by Joshua L. Krieger, Xuelin Li, Richard T. Thakor

    How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using the Food and Drug Administration public health advisories as idiosyncratic negative shocks to approved drugs, we examine how drug makers react through investment decisions. Following these shocks, affected firms increase research and development (R&D) expenditures, driven by a higher likelihood of acquiring external innovations rather than developing novel projects internally. Such acquisition activities are concentrated in firms with weak research pipelines. We also find that competing developers move resources away from the affected therapeutic areas. Our results show how investments in specialized commercialization capital create path dependencies and alter the direction of R&D investments. This paper was accepted by Ashish Arora, entrepreneurship and innovation.


  • Top Cited Papers

    Trials and Terminations: Learning from Competitors’ R&D Failures

    by Joshua L. Krieger

    I analyze project continuation decisions where firms may resolve uncertainty through news about competitors’ research and development (R&D) failures, as well as through their own results. I examine the tradeoffs and interactions between product-market competition and technological learning from parallel R&D projects. Leveraging the biopharmaceutical industry’s unique characteristics to overcome barriers to measuring project-level responses, I use a difference-in-differences strategy to evaluate how competitor exit news alters a firm’s own project discontinuation decisions. The findings reveal that technological learning dominates competition effects. Firms are most sensitive to competitor failure news from within the same market and same technology area—more than doubling their propensity to terminate drug development projects in the wake of this type of information. Finally, I explore how levels of competition, uncertainty, and opportunities to learn moderate the response to competitor failure news. This paper was accepted by Joshua Gans, business strategy.